<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02121158</url>
  </required_header>
  <id_info>
    <org_study_id>592</org_study_id>
    <nct_id>NCT02121158</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly</brief_title>
  <acronym>I-70</acronym>
  <official_title>CSP #592 - Efficacy and Safety of ICD Implantation in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this trial is to study the safety and efficacy of ICD implantation as a&#xD;
      primary prevention strategy of sudden cardiac death in patients 70 years and older. This&#xD;
      study will assess the many competing factors involved with ICD implantation including 1) the&#xD;
      impact on mortality, especially in the context of a declining rate of sudden death with&#xD;
      advanced age, 2) the tolerability of the powerful therapeutic action of the device, and 3)&#xD;
      the impact on quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall aim of this trial is to study the safety and efficacy of ICD implantation as a&#xD;
      primary prevention strategy of sudden cardiac death (SCD) in patients 70 years and older. In&#xD;
      particular, this study is designed to determine the comparative effectiveness of ICD, in&#xD;
      addition to optimal medical therapy (OMT), in reducing all-cause mortality, versus OMT alone;&#xD;
      OMT includes standard intervention for chronic heart failure patients, i.e. lifestyle&#xD;
      modification, disease management, adoption of healthy diet and exercise practices, etcetera.&#xD;
      One particularly important secondary objective is to assess treatment efficacy under the&#xD;
      conditions of high versus low co-morbidity burden.&#xD;
&#xD;
      Participants will be randomized (1:1 ratio) to ICD + OMT or OMT alone, and stratified by&#xD;
      participating site and co-morbidity level (Charlson score &lt;3 versus 3+). Acute treatment&#xD;
      visits will occur as clinically indicated and per local convention; follow-up will occur 1-4&#xD;
      months post-randomization (all participants), and not sooner than 30 days - and not later&#xD;
      than 120 days post-implantation (ICD arm); regular follow-up will occur at 6 month intervals&#xD;
      post-randomization until study close (all participants). All follow-up will be conducted&#xD;
      centrally. Neither the participant nor treating clinician will be masked to treatment.&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      The primary objective of this study is to determine if a primary prevention strategy with ICD&#xD;
      implantation in addition to optimal medical therapy (OMT) is effective in reducing all-cause&#xD;
      mortality compared to OMT alone in patients 70 years of age and older who are eligible for&#xD;
      ICD therapy according to current Centers for Medicare &amp; Medicaid Services (CMS) criteria.&#xD;
&#xD;
      Primary Hypothesis:&#xD;
&#xD;
      The primary hypothesis of this study is that implantation of an ICD plus optimal medical&#xD;
      therapy will reduce all-cause mortality in patients 70 years of age and older versus optimal&#xD;
      medical therapy alone.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. One secondary objective of this study is to ascertain whether age, co-morbidity burden,&#xD;
           or age and burden together, are determinants in mortality outcomes in the OMT versus ICD&#xD;
           + OMT group.&#xD;
&#xD;
        2. An additional secondary objective of the study is to determine the effect of ICD&#xD;
           implantation plus optimal medical therapy on quality of life among elderly patients&#xD;
           compared with optimal medical therapy alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 7, 2015</start_date>
  <completion_date type="Anticipated">November 6, 2021</completion_date>
  <primary_completion_date type="Actual">November 6, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To determine if a primary prevention strategy with ICD implantation in addition to optimal medical therapy (OMT) is effective in reducing all-cause mortality compared to OMT alone in patients &gt;=70 years of age who are eligible for ICD therapy according to current Centers for Medicare &amp; Medicaid Services (CMS) criteria.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiomyopathy</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Congestive Heart Failure</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ICD implantation in addition to Optimal Medical Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal Medical Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable Cardioverter Defibrillator</intervention_name>
    <description>The ICD and lead(s) will be FDA-approved.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optimal Medical Therapy</intervention_name>
    <description>Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 70 years of age or older&#xD;
&#xD;
          2. Eligible for ICD implementation according to the CMS criteria for primary prevention&#xD;
             by one of the following conditions:&#xD;
&#xD;
               1. Documented prior MI and a measured left ventricular ejection fraction (LVEF)&#xD;
                  &lt;=30% (includes New York Heart Association [NYHA] class I, II, or III)&#xD;
&#xD;
               2. Coronary artery disease with a documented prior MI, a measured left ventricular&#xD;
                  ejection fraction &lt;=35%, and inducible, sustained ventricular tachycardia (VT) or&#xD;
                  ventricular fibrillation (VF) at electrophysiology (EP) study&#xD;
&#xD;
               3. Ischemic dilated cardiomyopathy (IDCM), documented prior MI, NYHA class II and&#xD;
                  III heart failure, and measured LVEF &lt;=35%&#xD;
&#xD;
               4. Non-ischemic dilated cardiomyopathy (NIDCM) &gt; 3 months, NYHA Class II and III&#xD;
                  heart failure, and measured LVEF &lt;=35%&#xD;
&#xD;
          3. Stable condition on Optimal Medical Therapy&#xD;
&#xD;
          4. Able and willing to provide informed consent to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Enrolled in or planning to enroll in a conflicting trial&#xD;
&#xD;
          2. Receiving a bi-ventricular ICD device&#xD;
&#xD;
          3. New York Heart Association class IV heart failure&#xD;
&#xD;
          4. Cardiogenic shock or symptomatic hypotension while in stable baseline rhythm,&#xD;
&#xD;
          5. Coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty&#xD;
             (PTCA) within the past 3 months&#xD;
&#xD;
          6. An MI within the past 40 days&#xD;
&#xD;
          7. Clinical symptoms or findings that would make them a candidate for coronary&#xD;
             revascularization&#xD;
&#xD;
          8. Irreversible brain damage from pre-existing cerebral disease&#xD;
&#xD;
          9. Any disease other than cardiac disease (e.g. cancer, uremia, liver failure),&#xD;
             associated with a likelihood of survival less than 1 year&#xD;
&#xD;
         10. Circumstance that would prevent completion of the trial and follow-up activities,&#xD;
             including medical condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Singh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Washington DC VA Medical Center, Washington, DC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington DC VA Medical Center, Washington, DC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Florida/South Georgia Veterans Health System, Gainesville, FL</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Health Care System, Minneapolis, MN</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Portland Health Care System, Portland, OR</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Valley Healthcare System Nashville Campus, Nashville, TN</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-2637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 16, 2014</study_first_submitted>
  <study_first_submitted_qc>April 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2014</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CSP 592</keyword>
  <keyword>ICD</keyword>
  <keyword>cardiovascular</keyword>
  <keyword>heart</keyword>
  <keyword>aging</keyword>
  <keyword>chronic diseases</keyword>
  <keyword>multi-site trial</keyword>
  <keyword>investigational device</keyword>
  <keyword>cardiomyopathy</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>congestive heart failure</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>I-70</keyword>
  <keyword>I70</keyword>
  <keyword>elderly</keyword>
  <keyword>defibrillator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 5, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

